Back to results
US 10,245,317 B2Granted
Immunogenic composition
AssigneeGlaxosmithkline Biologicals SA
InventorsRalph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
Life of this patent
Estimating the term…
Abstract
The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s).
Claims11
An immunogenic composition, comprising:
- (a) a Neisseria meningitidis (N. meningitides) serogroup A capsular saccharide conjugated to an adipic acid dihydrazide (ADH) linker, wherein the linker is conjugated to tetanus toxoid carrier protein;
- (b) a N. meningitidis serogroup C capsular saccharide conjugated to an adipic acid dihydrazide (ADH) linker, wherein the linker is conjugated to tetanus toxoid carrier protein;
- (c) a N. meningitidis serogroup W capsular saccharide directly conjugated to tetanus toxoid carrier protein in the absence of a linker;
- and
- (d) a N. meningitidis serogroup Y capsular saccharide directly conjugated to tetanus toxoid carrier protein in the absence of a linker;
- wherein the ratio of Men A saccharide to carrier protein is between 1:2 to 1:5 (w/w);
- and wherein the ratio of MenC saccharide to carrier protein is between 1:2 to 1:5 (w/w).
4 more elements
Dependencies are inferred from the claim text.